论文部分内容阅读
阿司匹林仅作用于凝血烷诱发的血小板凝集，糖蛋白Ⅱb／Ⅲa抗体安全性低，而新一代P2T嘌呤受体拮抗剂可能成为更有效的抗栓药，它能有效地、选择性地阻断血小板上P2T嘌呤受体，从而消除血栓并抑制ADP诱导的血小板凝集，且作用迅速、可逆，但维持时间短，Ⅰ期临床研究与动物实验结果一致。鉴于此类药物的特点，作者通过大量体内外研究证明了内源性ADP在血栓形成中的作用。并将进行进一步临床研究，评价该类药物的体内疗效。
Aspirin acts only on thromboxane-induced platelet aggregation, and glycoprotein IIb / IIIa antibodies are less safe, whereas a new generation of P2T purinergic receptor antagonists may be more effective as antithrombotic agents that effectively and selectively block platelets P2T purinergic receptors, thereby eliminating thrombus and inhibiting ADP-induced platelet aggregation, and the role of rapid and reversible, but the maintenance of time is short, the phase Ⅰ clinical research and animal experiments consistent. Given the characteristics of these drugs, the authors demonstrate the role of endogenous ADP in thrombosis through extensive in vitro and in vivo studies. Further clinical studies will be conducted to evaluate the in vivo efficacy of these drugs.